You are here: Home Reviews Actos (pioglitazone HCI)



Actos is not the first drug of choice for the treatment of type 2 diabetes mellitus and should not be used as a mono-therapy. Combination-therapy with insulin is contraindicated. Since there is only limited documentation of the efficacy – including mortality and late diabetic complications – the medicinal product should only be used for patients, for whom dietary changes and maximum tolerable dose of traditional peroral antidiabetics are proven inadequate. In addition, the high cost of the drug should be considered before choosing the treatment.


Marketed in Denmark on November 24th 2000.

Last modified: November 29th 2005

Page last updated: 29 November 2005 Print Printspacer Tip a friend Tip a friend spacerTo the top To the top